{"id":390141,"date":"2020-11-27T00:00:00","date_gmt":"2020-11-27T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/conccv0001-2020-biopharma-heart-failure-china-in-depth-china-2020\/"},"modified":"2026-03-31T10:44:13","modified_gmt":"2026-03-31T10:44:13","slug":"conccv0001-2020-biopharma-heart-failure-china-in-depth-china-2020","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/conccv0001-2020-biopharma-heart-failure-china-in-depth-china-2020\/","title":{"rendered":"Heart failure | China In-Depth | China | 2020"},"content":{"rendered":"

Heart failure is a major public health burden in China. With a rapidly rising urban population and a growing trend in unhealthy lifestyles, heart failure is expected to affect a sizable population in the country. Although the treatment of acute heart failure (AHF) is dominated by older, cost-effective generic drugs, we expect the growing uptake of recently approved SGLT-2 inhibitors\u2014dapagliflozin (Bristol Myers Squibb\u2019s Farxiga) and empagliflozin (Boehringer Ingelheim\u2019s Jardiance)\u2014to boost the heart failure market. However, a significant unmet need exists for the treatment of chronic heart failure (CHF) with preserved ejection fraction, where treatment options are limited, representing an opportunity for drug developers. In addition, the ongoing reforms in the regulatory and A&R landscape of China are expected to encourage MNCs to enter the heart failure market.<\/p>\n

QUESTIONS ANSWERED<\/strong><\/p>\n

    \n
  1. How large is China\u2019s drug-treatable heart failure population, and how will the drug-treatment rate change during the forecast period?<\/li>\n
  2. What are the most commercially relevant drugs in China\u2019s heart failure market, and why? What are interviewed experts\u2019 insights into current treatment options? Which clinical needs remain unfulfilled?<\/li>\n
  3. What are the key market access considerations for key therapies in the heart failure pipeline in China? What sales\/uptake could they secure in heart failure?<\/li>\n
  4. What are the key drivers and constraints in the Chinese heart failure market, and how will the market evolve over the forecast period?<\/li>\n<\/ol>\n

    PRODUCT DESCRIPTION<\/strong><\/p>\n

    China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific A&R environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.<\/p>\n

    RELEASE DATE<\/strong><\/p>\n

    July 2020<\/p>\n

    GEOGRAPHY<\/strong><\/p>\n

    China<\/p>\n

    PRIMARY RESEARCH<\/strong><\/p>\n

    Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and 50 surveys with cardiologists Supported by survey data collected for this and other DRG research epidemiology Diagnosed prevalence of heart failure in urban versus rural China; clinically relevant and market-relevant drug-treatable populations.<\/p>\n

    FORECAST<\/strong><\/p>\n

    10-year, annualized, drug-level sales and patient shares of key heart failure regimens through 2029, based on primary and secondary market research to formulate bottom-up assumptions<\/p>\n

    EMERGING THERAPIES<\/strong><\/p>\n

    Phase III\/PR: 5+ drugs; Phase II: 3 drugs; coverage of select Phase I products<\/p>\n","protected":false},"template":"","class_list":["post-390141","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-acute-heart-failure","biopharma-therapy-areas-heart-failure","biopharma-product-china-in-depth","biopharma-geography-china","biopharma-date-942"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390141","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390141\/revisions"}],"predecessor-version":[{"id":576473,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390141\/revisions\/576473"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390141"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}